Abdominal Imaging

, Volume 38, Issue 1, pp 1–21

Complications of oncologic therapy in the abdomen and pelvis: a review

  • Dhakshina Moorthy Ganeshan
  • Usama Salem
  • Chitra Viswanathan
  • Aparna Balachandran
  • Naveen Garg
  • Paul Silverman
  • Priya Bhosale


Cancer therapy has significantly improved in the past few decades with development of various newer classes of cytotoxic chemotherapy as well as novel, molecularly targeted chemotherapy. Similar to chemotherapy, radiotherapy is another important therapeutic option used in the curative and palliative management of various abdominal malignancies. However, both these treatments affect the tumor as well as the normal tissues, leading to significant toxicity. These side effects range from mild to life threatening, and may involve multiple organs. Imaging plays an important role in the early identification of such complications, which may allow more effective patient management. The aim of this article is to discuss and illustrate the wide spectrum of chemotherapy and radiotherapy induced complications in the abdomen and pelvis.


Cancer therapy complications Abdominal imaging Pelvic imaging Chemotherapy complications Radiotherapy complications 


  1. 1.
    Kwek JW, Iyer RB, Dunnington J, Faria S, Silverman PM (2006) Spectrum of imaging findings in the abdomen after radiotherapy. AJR Am J Roentgenol 187(5):1204–1211. doi:10.2214/ajr.05.0941 PubMedCrossRefGoogle Scholar
  2. 2.
    Yeoh EK, Horowitz M (1987) Radiation enteritis. Surg Gynecol Obstet 165(4):373–379PubMedGoogle Scholar
  3. 3.
    Lawrence TS, Robertson JM, Anscher MS, et al. (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31(5):1237–1248PubMedCrossRefGoogle Scholar
  4. 4.
    Hall DA, Clouse ME, Gramm HF (1981) Gastroduodenal ulceration after hepatic arterial infusion chemotherapy. AJR Am J Roentgenol 136(6):1216–1218PubMedGoogle Scholar
  5. 5.
    Hohn DC, Stagg RJ, Price DC, Lewis BJ (1985) Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. J Clin Oncol 3(9):1257–1260PubMedGoogle Scholar
  6. 6.
    Kelvin FM, Gramm HF, Gluck WL, Lokich JJ (1986) Radiologic manifestations of small-bowel toxicity due to floxuridine therapy. AJR Am J Roentgenol 146(1):39–43PubMedGoogle Scholar
  7. 7.
    Torrisi JM, Schwartz LH, Gollub MJ, et al. (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56. doi:10.1148/radiol.10092129 PubMedCrossRefGoogle Scholar
  8. 8.
    Davila M, Bresalier RS (2008) Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 5(12):682–696. doi:10.1038/ncpgasthep1277 PubMedCrossRefGoogle Scholar
  9. 9.
    Benson AB 3rd, Ajani JA, Catalano RB, et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926PubMedCrossRefGoogle Scholar
  10. 10.
    Ikuno N, Soda H, Watanabe M, Oka M (1995) Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 87(24):1876–1883PubMedCrossRefGoogle Scholar
  11. 11.
    Tavakkolizadeh A, Shen R, Abraham P, et al. (2000) Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J Surg Res 91(1):77–82PubMedCrossRefGoogle Scholar
  12. 12.
    Douillard JY, Cunningham D, Roth AD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047PubMedCrossRefGoogle Scholar
  13. 13.
    Kuebler JP, Colangelo L, O’Connell MJ, et al. (2007) Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer 110(9):1945–1950PubMedCrossRefGoogle Scholar
  14. 14.
    Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19(18):3801–3807PubMedGoogle Scholar
  15. 15.
    Saltz LB, Cox JV, Blanke C, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914PubMedCrossRefGoogle Scholar
  16. 16.
    Zamani R, Heldmann M (2004) Enteritis as a complication of adjuvant combination chemotherapy using 5-fluorouracil and leukovorin: clinical and helical computed tomographic features. J La State Med Soc 156(3):143–144PubMedGoogle Scholar
  17. 17.
    Asnacios A, Naveau S, Perlemuter G (2009) Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer 45(Suppl 1):332–342. doi:10.1016/s0959-8049(09)70047-4 PubMedCrossRefGoogle Scholar
  18. 18.
    Harandi A, Zaidi AS, Stocker AM, Laber DA (2009) Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009:567486PubMedCrossRefGoogle Scholar
  19. 19.
    Cronin CG, O’Connor M, Lohan DG, et al. (2009) Imaging of the gastrointestinal complications of systemic chemotherapy. Clin Radiol 64(7):724–733PubMedCrossRefGoogle Scholar
  20. 20.
    Toghill PJ, Burke JD (1970) Death from paralytic ileus following vincristine therapy. Postgrad Med J 46(535):330–331PubMedCrossRefGoogle Scholar
  21. 21.
    Hashimoto S, Saitoh H, Wada K, et al. (1995) Pneumatosis cystoides intestinalis after chemotherapy for hematological malignancies: report of 4 cases. Intern Med 34(3):212–215PubMedCrossRefGoogle Scholar
  22. 22.
    St Peter SD, Abbas MA, Kelly KA (2003) The spectrum of pneumatosis intestinalis. Arch Surg 138(1):68–75PubMedCrossRefGoogle Scholar
  23. 23.
    Shanbhogue AK, Virmani V, Vikram R, et al. (2011) Spectrum of medication-induced complications in the abdomen: role of cross-sectional imaging. AJR Am J Roentgenol 197(2):W286–W294. doi:10.2214/ajr.10.5415 PubMedCrossRefGoogle Scholar
  24. 24.
    Gorschluter M, Mey U, Strehl J, et al. (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75(1):1–13. doi:10.1111/j.1600-0609.2005.00442.x PubMedCrossRefGoogle Scholar
  25. 25.
    Wade DS, Nava HR, Douglass HO Jr (1992) Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69(1):17–23PubMedCrossRefGoogle Scholar
  26. 26.
    Frick MP, Maile CW, Crass JR, Goldberg ME, Delaney JP (1984) Computed tomography of neutropenic colitis. AJR Am J Roentgenol 143(4):763–765PubMedGoogle Scholar
  27. 27.
    Kirkpatrick ID, Greenberg HM (2003) Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology 226(3):668–674PubMedCrossRefGoogle Scholar
  28. 28.
    Thoeni RF, Cello JP (2006) CT imaging of colitis. Radiology 240(3):623–638. doi:10.1148/radiol.2403050818 PubMedCrossRefGoogle Scholar
  29. 29.
    Ibrahim NK, Sahin AA, Dubrow RA, et al. (2000) Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 355(9200):281–283. doi:10.1016/s0140-6736(99)06195-4 PubMedCrossRefGoogle Scholar
  30. 30.
    Kreis W, Petrylak D, Savarese D, Budman D (2000) Colitis and docetaxel-based chemotherapy. Lancet 355(9221):2164. doi:10.1016/s0140-6736(05)72789-6 PubMedCrossRefGoogle Scholar
  31. 31.
    Anand A, Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17(1):109–113PubMedCrossRefGoogle Scholar
  32. 32.
    Macari M, Balthazar EJ, Megibow AJ (1999) The accordion sign at CT: a nonspecific finding in patients with colonic edema. Radiology 211(3):743–746PubMedGoogle Scholar
  33. 33.
    Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559–568PubMedCrossRefGoogle Scholar
  34. 34.
    Bonifazi M, Rossi M, Moja L, et al. (2012) Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist 17(1):117–124. doi:10.1634/theoncologist.2011-0184 PubMedCrossRefGoogle Scholar
  35. 35.
    Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3–6. doi:10.1016/j.ygyno.2007.01.038 PubMedCrossRefGoogle Scholar
  36. 36.
    Garant A, Des Groseilliers S, Martin L, Ferland E, Vuong T (2011) Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer. Clin Oncol 23(7):497–498. doi:10.1016/j.clon.2011.03.009 CrossRefGoogle Scholar
  37. 37.
    Rose PG, Piver MS (1995) Intestinal perforation secondary to paclitaxel. Gynecol Oncol 57(2):270–272. doi:10.1006/gyno.1995.1140 PubMedCrossRefGoogle Scholar
  38. 38.
    Liaw CC, Huang JS, Wang HM, Wang CH (1993) Spontaneous gastroduodenal perforation in patients with cancer receiving chemotherapy and steroids. Report of four cases combining 5-fluorouracil infusion and cisplatin with antiemetics dexamethasone. Cancer 72(4):1382–1385PubMedCrossRefGoogle Scholar
  39. 39.
    Schwartzentruber D, Lotze MT, Rosenberg SA (1988) Colonic perforation. An unusual complication of therapy with high-dose interleukin-2. Cancer 62(11):2350–2353PubMedCrossRefGoogle Scholar
  40. 40.
    Hecker A, Hecker B, Bassaly B, et al. (2010) Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. World J Surg Oncol 8:47. doi:10.1186/1477-7819-8-47 PubMedCrossRefGoogle Scholar
  41. 41.
    Hong X, Choi H, Loyer EM, et al. (2006) Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 26(2):481–495PubMedCrossRefGoogle Scholar
  42. 42.
    Talamonti MS, Dawes LG, Joehl RJ, Nahrwold DL (1990) Gastrointestinal lymphoma. A case for primary surgical resection. Arch Surg 125(8):972–976 ((discussion 976–977))PubMedCrossRefGoogle Scholar
  43. 43.
    Meyers PA, Potter VP, Wollner N, Exelby P (1985) Bowel perforation during initial treatment for childhood non-Hodgkin’s lymphoma. Cancer 56(2):259–261PubMedCrossRefGoogle Scholar
  44. 44.
    Coia LR, Myerson RJ, Tepper JE (1995) Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys 31(5):1213–1236PubMedCrossRefGoogle Scholar
  45. 45.
    Henriksson R, Bergstrom P, Franzen L, Lewin F, Wagenius G (1999) Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Acta Oncol 38(2):159–164PubMedCrossRefGoogle Scholar
  46. 46.
    Wobbes T, Verschueren RC, Lubbers EJ, Jansen W, Paping RH (1984) Surgical aspects of radiation enteritis of the small bowel. Dis Colon Rectum 27(2):89–92PubMedCrossRefGoogle Scholar
  47. 47.
    Perrakis N, Athanassiou E, Vamvakopoulou D, et al. (2011) Practical approaches to effective management of intestinal radiation injury: benefit of resectional surgery. World J Gastroenterol 17(35):4013–4016. doi:10.3748/wjg.v17.i35.4013 PubMedCrossRefGoogle Scholar
  48. 48.
    Horton KM, Corl FM, Fishman EK (1999) CT of nonneoplastic diseases of the small bowel: spectrum of disease. J Comput Assist Tomogr 23(3):417–428PubMedCrossRefGoogle Scholar
  49. 49.
    Hauer-Jensen M (1990) Late radiation injury of the small intestine. Clinical, pathophysiologic and radiobiologic aspects. A review. Acta Oncol 29(4):401–415PubMedCrossRefGoogle Scholar
  50. 50.
    Capps GW, Fulcher AS, Szucs RA, Turner MA (1997) Imaging features of radiation-induced changes in the abdomen. Radiographics 17(6):1455–1473PubMedGoogle Scholar
  51. 51.
    Sugimura K, Carrington BM, Quivey JM, Hricak H (1990) Postirradiation changes in the pelvis: assessment with MR imaging. Radiology 175(3):805–813PubMedGoogle Scholar
  52. 52.
    Donner CS (1998) Pathophysiology and therapy of chronic radiation-induced injury to the colon. Dig Dis 16(4):253–261PubMedCrossRefGoogle Scholar
  53. 53.
    Khan AZ, Morris-Stiff G, Makuuchi M (2009) Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 16(2):137–144. doi:10.1007/s00534-008-0016-z PubMedCrossRefGoogle Scholar
  54. 54.
    Chun YS, Laurent A, Maru D, Vauthey JN (2009) Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10(3):278–286. doi:10.1016/s1470-2045(09)70064-6 PubMedCrossRefGoogle Scholar
  55. 55.
    McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40(Suppl 1):S17–S29. doi:10.1097/01.mcg.0000168645.86658.22 PubMedGoogle Scholar
  56. 56.
    Belghiti J, Hiramatsu K, Benoist S, et al. (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191(1):38–46PubMedCrossRefGoogle Scholar
  57. 57.
    Gomez D, Malik HZ, Bonney GK, et al. (2007) Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 94(11):1395–1402. doi:10.1002/bjs.5820 PubMedCrossRefGoogle Scholar
  58. 58.
    Kooby DA, Fong Y, Suriawinata A, et al. (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7(8):1034–1044PubMedCrossRefGoogle Scholar
  59. 59.
    Donadon M, Vauthey JN, Loyer EM, Charnsangavej C, Abdalla EK (2006) Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol 12(40):6556–6558PubMedGoogle Scholar
  60. 60.
    Vauthey JN, Pawlik TM, Ribero D, et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072. doi:10.1200/jco.2005.05.3074 PubMedCrossRefGoogle Scholar
  61. 61.
    Zorzi D, Laurent A, Pawlik TM, et al. (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94(3):274–286. doi:10.1002/bjs.5719 PubMedCrossRefGoogle Scholar
  62. 62.
    Hamer OW, Aguirre DA, Casola G, et al. (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26(6):1637–1653. doi:10.1148/rg.266065004 PubMedCrossRefGoogle Scholar
  63. 63.
    Joy D, Thava VR, Scott BB (2003) Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 15(5):539–543. doi:10.1097/01.meg.0000059112.41030.2e PubMedGoogle Scholar
  64. 64.
    Blachar A, Federle MP, Sosna J (2009) Liver lesions with hepatic capsular retraction. Semin Ultrasound CT MR 30(5):426–435PubMedCrossRefGoogle Scholar
  65. 65.
    Fennessy FM, Mortele KJ, Kluckert T, et al. (2004) Hepatic capsular retraction in metastatic carcinoma of the breast occurring with increase or decrease in size of subjacent metastasis. AJR Am J Roentgenol 182(3):651–655PubMedGoogle Scholar
  66. 66.
    Young ST, Paulson EK, Washington K, et al. (1994) CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 163(6):1385–1388PubMedGoogle Scholar
  67. 67.
    Qayyum A, Lee GK, Yeh BM, et al. (2007) Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging 31(1):6–10. doi:10.1016/j.clinimag.2006.09.028 PubMedCrossRefGoogle Scholar
  68. 68.
    Shirkhoda A, Baird S (1994) Morphologic changes of the liver following chemotherapy for metastatic breast carcinoma: CT findings. Abdom Imaging 19(1):39–42PubMedCrossRefGoogle Scholar
  69. 69.
    Cefalo MG, Maurizi P, Arlotta A, et al. (2010) Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies. Paediatr Drugs 12(5):277–284. doi:10.2165/11531840-000000000-00000 PubMedCrossRefGoogle Scholar
  70. 70.
    Lassau N, Leclere J, Auperin A, et al. (1997) Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology 204(2):545–552PubMedGoogle Scholar
  71. 71.
    Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB (1994) Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 19(5):1171–1181PubMedCrossRefGoogle Scholar
  72. 72.
    Robinson S, Manas DM, Pedley I, Mann D, White SA (2011) Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol 20(2):57–72. doi:10.1016/j.suronc.2009.10.002 PubMedCrossRefGoogle Scholar
  73. 73.
    Richardson P, Guinan E (1999) The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 107(3):485–493PubMedCrossRefGoogle Scholar
  74. 74.
    Erturk SM, Mortele KJ, Binkert CA, et al. (2006) CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. AJR Am J Roentgenol 186(6):1497–1501PubMedCrossRefGoogle Scholar
  75. 75.
    Mahgerefteh SY, Sosna J, Bogot N, et al. (2011) Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology 258(3):660–671. doi:10.1148/radiol.10100025 PubMedCrossRefGoogle Scholar
  76. 76.
    Nakano H, Oussoultzoglou E, Rosso E, et al. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247(1):118–124. doi:10.1097/SLA.0b013e31815774de PubMedCrossRefGoogle Scholar
  77. 77.
    Slade JH, Alattar ML, Fogelman DR, et al. (2009) Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 8(4):225–230. doi:10.3816/CCC.2009.n.038 PubMedCrossRefGoogle Scholar
  78. 78.
    Tisman G, MacDonald D, Shindell N, et al. (2004) Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22(15):3202–3204. doi:10.1200/jco.2004.99.106 PubMedCrossRefGoogle Scholar
  79. 79.
    Khozouz RF, Huq SZ, Perry MC (2008) Radiation-induced liver disease. J Clin Oncol 26(29):4844–4845PubMedCrossRefGoogle Scholar
  80. 80.
    Iyer RB, Balachandran A, Bruzzi JF, et al. (2007) PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 7:189–194. doi:10.1102/1470-7330.2007.0027 PubMedCrossRefGoogle Scholar
  81. 81.
    DeLappe EM, Truong MT, Bruzzi JF, Swisher SG, Rohren EM (2009) Hepatic radiation injury mimicking a metastasis on positron-emission tomography/computed tomography in a patient with esophageal carcinoma. J Thorac Oncol 4(11):1442–1444PubMedCrossRefGoogle Scholar
  82. 82.
    Mahmoud H, Schell M, Pui CH (1991) Cholelithiasis after treatment for childhood cancer. Cancer 67(5):1439–1442PubMedCrossRefGoogle Scholar
  83. 83.
    Buyukasik Y, Kosar A, Demiroglu H, et al. (1998) Acalculous acute cholecystitis in leukemia. J Clin Gastroenterol 27(2):146–148PubMedCrossRefGoogle Scholar
  84. 84.
    Kobbe G, Heyll A, Zodler T, et al. (1997) Acute acalculous cholecystitis complicating oral recontamination after allogeneic bone marrow transplantation. Oncol Rep 4(4):823–824PubMedGoogle Scholar
  85. 85.
    Barnett KT, Malafa MP (2001) Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer 30(3):147–160. doi:10.1385/ijgc:30:3:147 PubMedCrossRefGoogle Scholar
  86. 86.
    Sandrasegaran K, Alazmi WM, Tann M, et al. (2006) Chemotherapy-induced sclerosing cholangitis. Clin Radiol 61(8):670–678. doi:10.1016/j.crad.2006.02.013 PubMedCrossRefGoogle Scholar
  87. 87.
    Botet JF, Watson RC, Kemeny N, Daly JM, Yeh S (1985) Cholangitis complicating intraarterial chemotherapy in liver metastasis. Radiology 156(2):335–337PubMedGoogle Scholar
  88. 88.
    Phongkitkarun S, Kobayashi S, Varavithya V, et al. (2005) Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin Radiol 60(6):700–709. doi:10.1016/j.crad.2005.01.006 PubMedCrossRefGoogle Scholar
  89. 89.
    Morgan C, Tillett T, Braybrooke J, Ajithkumar T (2011) Management of uncommon chemotherapy-induced emergencies. Lancet Oncol 12(8):806–814. doi:10.1016/s1470-2045(10)70208-4 PubMedCrossRefGoogle Scholar
  90. 90.
    Sugarbaker PH, Alderman R, Edwards G, et al. (2006) Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 13(5):635–644PubMedCrossRefGoogle Scholar
  91. 91.
    Ruinemans GM, Balemans C, Mattijssen V, Wiersma-van Tilburg AJ, Smit HJ (2010) Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib. Lung Cancer 70(3):364–365. doi:10.1016/j.lungcan.2010.08.004 PubMedCrossRefGoogle Scholar
  92. 92.
    Motzer RJ, Rini BI, Bukowski RM, et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516–2524. doi:10.1001/jama.295.21.2516 PubMedCrossRefGoogle Scholar
  93. 93.
    Li M, Srinivas S (2007) Acute pancreatitis associated with sorafenib. South Med J 100(9):909–911PubMedCrossRefGoogle Scholar
  94. 94.
    Levy P, Menzelxhiu A, Paillot B, et al. (1993) Abdominal radiotherapy is a cause for chronic pancreatitis. Gastroenterology 105(3):905–909PubMedGoogle Scholar
  95. 95.
    Elliott MA, Mesa RA, Tefferi A (2002) Adverse events after imatinib mesylate therapy. N Engl J Med 346(9):712–713. doi:10.1056/NEJM200202283460919 PubMedCrossRefGoogle Scholar
  96. 96.
    Masood N, Shaikh AJ, Memon WA, Idress R (2008) Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 1(1):418PubMedCrossRefGoogle Scholar
  97. 97.
    Aapro MS, Cameron DA, Pettengell R, et al. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453. doi:10.1016/j.ejca.2006.05.002 PubMedCrossRefGoogle Scholar
  98. 98.
    Lionne-Huyghe P, Kuhnowski F, Coiteux V, Bauters F, Morschhauser F (2006) Indications of G-CSF administration in hematologic disorders. Bull Cancer 93(5):453–462PubMedGoogle Scholar
  99. 99.
    Tigue CC, McKoy JM, Evens AM, et al. (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transpl 40(3):185–192. doi:10.1038/sj.bmt.1705722 CrossRefGoogle Scholar
  100. 100.
    Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A (2006) Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 91(Suppl 5):ECR08PubMedGoogle Scholar
  101. 101.
    Hernandez R, del Canizo MC, Lopez C, et al. (2000) Pathologic rupture of the spleen during induction with ATRA in a patient with acute promyelocytic leukemia. Med Oncol 17(4):337–339PubMedCrossRefGoogle Scholar
  102. 102.
    Lubner M, Menias C, Rucker C, et al. (2007) Blood in the belly: CT findings of hemoperitoneum. Radiographics 27(1):109–125PubMedCrossRefGoogle Scholar
  103. 103.
    Miura K, Nakano H, Sakurai J, et al. (2011) Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol 16(3):257–263. doi:10.1007/s10147-010-0176-0 PubMedCrossRefGoogle Scholar
  104. 104.
    Overman MJ, Maru DM, Charnsangavej C, et al. (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28(15):2549–2555. doi:10.1200/jco.2009.27.5701 PubMedCrossRefGoogle Scholar
  105. 105.
    Ezra N, Goltche NB, Hakimian S, Afari A (2010) CTLA4-induced splenomegaly and a review of the literature pertaining to autoimmune complications of therapy. J Drugs Dermatol 9(11):1432–1436PubMedGoogle Scholar
  106. 106.
    Iyer R, Jhingran A (2006) Radiation injury: imaging findings in the chest, abdomen and pelvis after therapeutic radiation. Cancer Imaging 6:S131–S139. doi:10.1102/1470-7330.2006.9095 PubMedCrossRefGoogle Scholar
  107. 107.
    de Jonge MJ, Verweij J (2006) Renal toxicities of chemotherapy. Semin Oncol 33(1):68–73. doi:10.1053/j.seminoncol.2005.11.011 PubMedCrossRefGoogle Scholar
  108. 108.
    Kelly RJ, Billemont B, Rixe O (2009) Renal toxicity of targeted therapies. Target Oncol 4(2):121–133. doi:10.1007/s11523-009-0109-x PubMedCrossRefGoogle Scholar
  109. 109.
    Del Toro G, Morris E, Cairo MS (2005) Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 3(1):54–61PubMedGoogle Scholar
  110. 110.
    Davidson MB, Thakkar S, Hix JK, et al. (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116(8):546–554. doi:10.1016/j.amjmed.2003.09.045 PubMedCrossRefGoogle Scholar
  111. 111.
    Jones DP, Mahmoud H, Chesney RW (1995) Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9(2):206–212PubMedCrossRefGoogle Scholar
  112. 112.
    Coiffier B, Altman A, Pui CH, Younes A, Cairo MS (2008) Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 26(16):2767–2778. doi:10.1200/jco.2007.15.0177 PubMedCrossRefGoogle Scholar
  113. 113.
    Stillwell TJ, Benson RC Jr (1988) Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 61(3):451–457PubMedCrossRefGoogle Scholar
  114. 114.
    Talar-Williams C, Hijazi YM, Walther MM, et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124(5):477–484PubMedGoogle Scholar
  115. 115.
    Benya EC, Sivit CJ, Quinones RR (1993) Abdominal complications after bone marrow transplantation in children: sonographic and CT findings. AJR Am J Roentgenol 161(5):1023–1027PubMedGoogle Scholar
  116. 116.
    Coy DL, Ormazabal A, Godwin JD, Lalani T (2005) Imaging evaluation of pulmonary and abdominal complications following hematopoietic stem cell transplantation. Radiographics 25(2):305–317 ((discussion 318)). doi:10.1148/rg.252045037 PubMedCrossRefGoogle Scholar
  117. 117.
    McCarville MB, Hoffer FA, Gingrich JR, Jenkins JJ III (2000) Imaging findings of hemorrhagic cystitis in pediatric oncology patients. Pediatr Radiol 30(3):131–138PubMedCrossRefGoogle Scholar
  118. 118.
    Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D (2008) Urological implications of cyclophosphamide and ifosfamide. Scand J Urol Nephrol 42(4):309–317. doi:10.1080/00365590701570953 PubMedCrossRefGoogle Scholar
  119. 119.
    Wheeler JS Jr, Siroky MB, Bell R, Babayan RK (1983) Vincristine-induced bladder neuropathy. J Urol 130(2):342–343PubMedGoogle Scholar
  120. 120.
    Shimura K, Shimazaki C, Taniguchi K, et al. (2009) Bortezomib-induced neurogenic bladder in patients with multiple myeloma. Ann Hematol 88(4):383–384. doi:10.1007/s00277-008-0614-5 PubMedCrossRefGoogle Scholar
  121. 121.
    Citak EC, Oguz A, Karadeniz C, et al. (2008) Vincristine-induced peripheral neuropathy and urinary bladder paralysis in a child with rhabdomyosarcoma. J Pediatr Hematol Oncol 30(1):61–62. doi:10.1097/MPH.0b013e318158343b PubMedCrossRefGoogle Scholar
  122. 122.
    Charnsangavej C, Cinqualbre A, Wallace S (1994) Radiation changes in the liver, spleen, and pancreas: imaging findings. Semin Roentgenol 29(1):53–63PubMedCrossRefGoogle Scholar
  123. 123.
    Marks LB, Carroll PR, Dugan TC, Anscher MS (1995) The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31(5):1257–1280PubMedCrossRefGoogle Scholar
  124. 124.
    Addar MH, Stuart GC, Nation JG, Shumsky AG (1996) Spontaneous rupture of the urinary bladder: a late complication of radiotherapy—case report and review of the literature. Gynecol Oncol 62(2):314–316. doi:10.1006/gyno.1996.0234 PubMedCrossRefGoogle Scholar
  125. 125.
    Parliament M, Genest P, Girard A, Gerig L, Prefontaine M (1989) Obstructive ureteropathy following radiation therapy for carcinoma of the cervix. Gynecol Oncol 33(2):237–240PubMedCrossRefGoogle Scholar
  126. 126.
    Ascher SM, Imaoka I, Lage JM (2000) Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 214(1):29–38PubMedGoogle Scholar
  127. 127.
    Fong K, Causer P, Atri M, Lytwyn A, Kung R (2003) Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 23(1):137–150 ((discussion 151–135))PubMedCrossRefGoogle Scholar
  128. 128.
    Cohen I (2004) Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 94(2):256–266. doi:10.1016/j.ygyno.2004.03.048 PubMedCrossRefGoogle Scholar
  129. 129.
    Kazerooni T, Ghaffarpasand F, Mosalaei A, Kazerooni Y (2010) The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Med Princ Pract 19(3):222–227. doi:10.1159/000285296 PubMedCrossRefGoogle Scholar
  130. 130.
    Manfredi R, Gui B, Maresca G, Fanfani F, Bonomo L (2005) Endometrial cancer: magnetic resonance imaging. Abdom Imaging 30(5):626–636. doi:10.1007/s00261-004-0298-9 PubMedCrossRefGoogle Scholar
  131. 131.
    Weaver J, McHugo JM, Clark TJ (2005) Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen. Br J Radiol 78(929):394–397. doi:10.1259/bjr/60976544 PubMedCrossRefGoogle Scholar
  132. 132.
    Addley HC, Vargas HA, Moyle PL, Crawford R, Sala E (2010) Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies. Radiographics 30(7):1843–1856. doi:10.1148/rg.307105063 PubMedCrossRefGoogle Scholar
  133. 133.
    Elice F, Rodeghiero F, Falanga A, Rickles FR (2009) Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22(1):115–128. doi:10.1016/j.beha.2009.01.001 PubMedCrossRefGoogle Scholar
  134. 134.
    Harding GE, Lawlor DK (2007) Ruptured mycotic abdominal aortic aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guerin. J Vasc Surg 46(1):131–134. doi:10.1016/j.jvs.2007.01.054 PubMedCrossRefGoogle Scholar
  135. 135.
    Fajardo LF (1999) Is the pathology of radiation injury different in small vs. large blood vessels? Cardiovasc Radiat Med 1(1):108–110PubMedCrossRefGoogle Scholar
  136. 136.
    Libshitz HI (1994) Radiation changes in bone. Semin Roentgenol 29(1):15–37PubMedCrossRefGoogle Scholar
  137. 137.
    Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56(1):83–88PubMedCrossRefGoogle Scholar
  138. 138.
    Sheppard DG, Libshitz HI (2001) Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol 56(1):22–29. doi:10.1053/crad.2000.0599 PubMedCrossRefGoogle Scholar
  139. 139.
    Schmit M, Bethge W, Beck R, et al. (2008) CT of gastrointestinal complications associated with hematopoietic stem cell transplantation. AJR Am J Roentgenol 190(3):712–719PubMedCrossRefGoogle Scholar
  140. 140.
    Thomas ED (1999) Bone marrow transplantation: a review. Semin Hematol 36(4 Suppl 7):95–103PubMedGoogle Scholar
  141. 141.
    Levine DS, Navarro OM, Chaudry G, Doyle JJ, Blaser SI (2007) Imaging the complications of bone marrow transplantation in children. Radiographics 27(2):307–324PubMedCrossRefGoogle Scholar
  142. 142.
    Jones B, Fishman EK, Kramer SS, et al. (1986) Computed tomography of gastrointestinal inflammation after bone marrow transplantation. AJR Am J Roentgenol 146(4):691–695PubMedGoogle Scholar
  143. 143.
    Scarsbrook AF, Warakaulle DR, Dattani M, Traill Z (2005) Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol 60(1):47–55. doi:10.1016/j.crad.2004.08.016 PubMedCrossRefGoogle Scholar
  144. 144.
    Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphanet J Rare Dis 2:35. doi:10.1186/1750-1172-2-35 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Dhakshina Moorthy Ganeshan
    • 1
  • Usama Salem
    • 1
    • 2
  • Chitra Viswanathan
    • 1
  • Aparna Balachandran
    • 1
  • Naveen Garg
    • 1
  • Paul Silverman
    • 1
  • Priya Bhosale
    • 1
  1. 1.Department of Diagnostic RadiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Diagnostic RadiologyNational Cancer Institute, Cairo UniversityCairoEgypt

Personalised recommendations